Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others), By Region (North America, Europe, APAC, Latin America, MEA) and By Country (USA, Canada, UK, Germany, Japan, Brazil, South Africa).
The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to supress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.
Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period. While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population. Global Pulmonary Arterial Hypertension Market is forecasted to grow at a CAGR of 4.95% during 2016 – 2021F, on account of rising prevalence of the PAH disease among the population.
North America region remains the major market followed by Europe in the actual period. In the forecast period, APAC region will witness strong growth driven by the countries such as India and China.
According to Azoth Analytics research report, Global Pulmonary Arterial Hypertension Market: Trends, Opportunities and Forecasts (2016-2021), Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over ~4.95% during 2016 - 2021. On the basis of market segment, Global Pulmonary Arterial Hypertension Market has been segmented By Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V Inhibitors, Others; By Region-North America, Europe, APAC, Latin America, MEA; By Country- USA, Canada, UK, Germany, Japan, Brazil, South Africa)
Scope of the Report The report provides Segmentation by Drug Class - Endothelin receptor antagonists - Prostacyclin and Prostacyclin Analogs - Phosphodiesterase V Inhibitors - Others
The report provides coverage by Region - North America - Europe - Asia Pacific - Latin America - Middle East and Africa (MEA)
The report provides coverage by Country - USA - Canada - UK - Germany - Japan - Brazil - South Africa
Customization of the Report The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
Our reports have been used by over 10K customers, including:
213 pages •
By Asia Market Information & Development Company
• Jun 2020
China’s demand for Respiratory Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes....
Soluble Guanylate Cyclase - Pipeline Review, H1 2020 Summary Soluble Guanylate Cyclase (sGC or EC 126.96.36.199) – Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP....
Type 2 Diabetes - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes – Pipeline Review, H1 2020, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape. Type 2 diabetes is a chronic condition and is...
Malaria - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Malaria – Pipeline Review, H1 2020, provides an overview of the Malaria (Infectious Disease) pipeline landscape. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium)...
The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025). The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.